Ascentage Pharma Group International Inc. announced an offshore transaction to offer ordinary shares to non-U.S. persons, subject to market conditions. The net proceeds will be used for commercialization efforts and global clinical development. The lead asset olverembatinib is the first novel third-generation BCR-ABL1 inhibitor approved in China. The second lead asset lisaftoclax is a novel Bcl-2 inhibitor for hematologic malignancies. Ascentage Pharma has partnerships with leading biotech and pharmaceutical companies. Forward-looking statements caution investors about risks and uncertainties. Contacts for investor and media relations are provided for more information.

Read more at GlobeNewswire: Ascentage Pharma Announces Proposed Top-Up Placement